Troglitazone prevents mitochondrial alterations, β cell destruction, and diabetes in obese prediabetic rats
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To determine whether the antidiabetic action of troglitazone (TGZ), heretofore attributed to insulin sensitization, also involves protection of β cells from lipoapoptosis, we treated prediabetic Zucker Diabetic Fatty rats with 200 mg/kg per day of TGZ. Their plasma-free fatty acids and triacylglycerol fell to 1.3 mM and 111 mg/dl, respectively, compared with 2.0 mM and 560 mg/dl in untreated controls. Their islet triacylglycerol content was 34% below controls. In islets of control rats, β cells were reduced by 82% and the islet architecture was disrupted; β-cell glucose transporter-2 was absent, 85% of their mitochondria were altered, and they were unresponsive to glucose. In treated rats, the loss of β cells was prevented, as were the loss of β cell glucose transporter-2, the mitochondrial alterations, and the impairment of glucose-stimulated insulin secretion. We conclude that the antidiabetic effect of TGZ in prediabetic Zucker Diabetic Fatty rats involves prevention of lipotoxicity and lipoapoptosis of β cells, as well as improvement in insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Fatty acid-induced β cell apoptosis: A link between obesity and diabetes
Shimabukuro, M., Zhou, Y.-T., Levi, M., & Unger, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2498 · Cited by 1,142
Self-citationZhou, Y. P., & Grill, V. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117042 · Cited by 677
Self-citationRegulation of fatty acid homeostasis in cells: Novel role of leptin
Unger, R. H., Zhou, Y.-T., & Orci, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2327 · Cited by 435
Self-citationCavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Lipotoxic heart disease in obese rats: Implications for human obesity
Zhou, Y.-T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., Baetens, D., Orci, L., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1784 · Cited by 1,265
Self-citationGlucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092
Lipotoxicity: when tissues overeat
Schaffer, J. E. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200306000-00008 · Cited by 896
Adiponectin Expression From Human Adipose Tissue
Kern, P. A., Di Gregorio, G. B., Lu, T., Rassouli, N., & Ranganathan, G. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1779 · Cited by 875
“Troglitazone and other peroxisome proliferator activated receptor- agonists increase adiponectin levels (35–37), lower islet lipid content, and improve -cell function in Zucker diabetic rats (41).”
BackgroundUnger, R. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104057 · Cited by 875
Self-citationWeyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Leptin Signaling, Adiposity, and Energy Balance
JÉQUIER, E. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04293.x · Cited by 789
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Nuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Lupi, R., Dotta, F., Marselli, L., Del Guerra, S., Masini, M., Santangelo, C., Patané, G., Boggi, U., Piro, S., Anello, M., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1437 · Cited by 595
Lipid homeostasis, lipotoxicity and the metabolic syndrome
Unger, R. H., Clark, G. O., Scherer, P. E., & Orci, L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.006 · Cited by 511
Self-citationLipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Unger, R. H., & Zhou, Y. T. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s118 · Cited by 482
Self-citationAn, J., Muoio, D. M., Shiota, M., Fujimoto, Y., Cline, G. W., Shulman, G. I., Koves, T. R., Stevens, R., Millington, D., & Newgard, C. B. (2004) · Nature Medicine · doi:10.1038/nm995 · Cited by 450
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Diseases of liporegulation: new perspective on obesity and related disorders
UNGER, R. H., & ORCI, L. (2001) · The FASEB Journal · doi:10.1096/fj.00-0590 · Cited by 430
Self-citationBrunham, L. R., Kruit, J. K., Pape, T. D., Timmins, J. M., Reuwer, A. Q., Vasanji, Z., Marsh, B. J., Rodrigues, B., Johnson, J. D., Parks, J. S., et al. (2007) · Nature Medicine · doi:10.1038/nm1546 · Cited by 414
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
β-Cell Mass Dynamics in Zucker Diabetic Fatty Rats
Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G., Leonard, T., & Buckingham, R. E. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1021 · Cited by 374
Lipoapoptosis: its mechanism and its diseases
Unger, R. H., & Orci, L. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00342-6 · Cited by 361
Self-citationIsomer-Specific Antidiabetic Properties of Conjugated Linoleic Acid
Ryder, J. W., Portocarrero, C. P., Song, X. M., Cui, L., Yu, M., Combatsiaris, T., Galuska, D., Bauman, D. E., Barbano, D. M., Charron, M. J., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1149 · Cited by 316
Diabetes and apoptosis: lipotoxicity
Kusminski, C. M., Shetty, S., Orci, L., Unger, R. H., & Scherer, P. E. (2009) · Apoptosis · doi:10.1007/s10495-009-0352-8 · Cited by 302
Self-citationFatty Acid-Induced Lipotoxicity in Pancreatic Beta-Cells During Development of Type 2 Diabetes
Oh, Y. S., Bae, G. D., Baek, D. J., Park, E.-Y., & Jun, H.-S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00384 · Cited by 306
Lipotoxicity, overnutrition and energy metabolism in aging
Slawik, M., & Vidal-Puig, A. J. (2006) · Ageing Research Reviews · doi:10.1016/j.arr.2006.03.004 · Cited by 300
Taylor, P. D., McConnell, J., Khan, I. Y., Holemans, K., Lawrence, K. M., Asare-Anane, H., Persaud, S. J., Jones, P. M., Petrie, L., Hanson, M. A., et al. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00355.2004 · Cited by 297
“Of particular relevence to the current study Higa and colleagues have reported altered mitochondrial morphology in isolated islets from Zucker Diabetic Fatty rats, associated with lipotoxicity and lipoapoptosis of β-cells (14).”
BackgroundBensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Viollet, B. (2009) · Frontiers in Bioscience · doi:10.2741/3460 · Cited by 278
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Kakuma, T., Lee, Y., Higa, M., Wang, Z.-W., Pan, W., Shimomura, I., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8536 · Cited by 261
Self-citationSzczepaniak, L. S., Victor, R. G., Orci, L., & Unger, R. H. (2007) · Circulation Research · doi:10.1161/circresaha.107.160457 · Cited by 257
Self-citationTargeting the pancreatic β-cell to treat diabetes
Vetere, A., Choudhary, A., Burns, S. M., & Wagner, B. K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4231 · Cited by 252
Preservation of β-Cell Function: The Key to Diabetes Prevention
DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Self-citationEpigenetic mechanisms in the development of type 2 diabetes
Pinney, S. E., & Simmons, R. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.10.002 · Cited by 205
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
“Conversely, treatment with TZDs has been shown to mobilize fat out of the -cells and enhance -cell function in these animal models of type 2 diabetes (18, 21, 29, 31, 36, 47, 55, 59).”
BackgroundInfluentialLongevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine
Unger, R. H. (2005) · Biochimie · doi:10.1016/j.biochi.2004.11.014 · Cited by 184
Self-citationCholesterol in islet dysfunction and type 2 diabetes
Brunham, L. R., Kruit, J. K., Verchere, C. B., & Hayden, M. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33296 · Cited by 158
“Rosiglitazone may also have beneficial effects on β cell function in humans (17) and β cell mass and function in animal models (18).”
BackgroundPioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met
Tomita, K., Azuma, T., Kitamura, N., Nishida, J., Tamiya, G., Oka, A., Inokuchi, S., Nishimura, T., Suematsu, M., & Ishii, H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.008 · Cited by 141
Ishida, H., Takizawa, M., Ozawa, S., Nakamichi, Y., Yamaguchi, S., Katsuta, H., Tanaka, T., Maruyama, M., Katahira, H., Yoshimoto, K., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.021 · Cited by 138
Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome
Correia, M. L. G., & Rahmouni, K. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00562.x · Cited by 121
Diani, A. R., Sawada, G., Wyse, B., Murray, F. T., & Khan, M. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00331.2003 · Cited by 100
“(44), as well as in other animal models of diabetes with rosiglitazone (5, 15, 42) and troglitazone (18, 39, 40).”
BackgroundInfluentialStructural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice
Kawasaki, F., Matsuda, M., Kanda, Y., Inoue, H., & Kaku, K. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00128.2004 · Cited by 99
Supale, S., Thorel, F., Merkwirth, C., Gjinovci, A., Herrera, P. L., Scorrano, L., Meda, P., Langer, T., & Maechler, P. (2013) · Diabetes · doi:10.2337/db13-0152 · Cited by 94
Hsueh, W., McLellan, K., Wyne, K., & Villagomez, E. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39564 · Cited by 91
Emerging roles of β-cell mitochondria in type-2-diabetes
Las, G., Oliveira, M. F., & Shirihai, O. S. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100843 · Cited by 51
Metadata
- Authors
- Higa, M., Zhou, Y.-T., Ravazzola, M., Baetens, D., Orci, L., & Unger, R. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-09-28
- Volume
- 96
- Issue
- 20
- Pages
- 11513-11518
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2085588685
- Cited by
- 235
- References
- 5
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.